How Are Payers Controlling Costs With New Hepatitis C Treatments?

The recent growth of Hepatitis C treatment, now has payers considering the HCV category right up there with cancer, rheumatoid arthritis, and multiple sclerosis. Take a look at the recent approval of new hepatitis C treatments in Specialty Pharmacy Times’, Keeping an Eye on Hepatitis C Virus Drug Approvals, available here. (Source: :Lee Goldberg, Specialty Pharmacy Times, 8/20/14).

You might also be interested in:

Executives Talk Blockchain, EMR with Value & Outcomes October 19, 2018
Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026 August 19, 2019
Time to Market: Accelerating Market Access January 4, 2019
BioNJ Releases White Paper on Demonstrating Value June 6, 2019
Fendrick, Klein Back Drug Rebate Proposal February 27, 2019
The Global Use of Medicine in 2019 and Outlook to 2023 January 29, 2019
Report: Times Vary Widely on Reimbursement Decisions for New… October 21, 2018